tailieunhanh - báo cáo khoa học: " Insights into gliomagenesis: systems biology unravels key pathways"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Insights into gliomagenesis: systems biology unravels key pathways | Genome Medicine Minireview Insights into gliomagenesis systems biology unravels key pathways Sandro J de Souza Beatriz Stranskyt and Anamaria A Camargo Addresses Ludwig Institute for Cancer Research São Paulo branch Rua João Julião 245 1 andar São Paulo 01323-903 Brazil. tCentro de Engenharia Modelagem e Ciências Sociais Aplicadas Universidade Federal do ABC Rua Santa Adélia 166 Bairro Bangu Santo André São Paulo 09210-170 Brazil. Correspondence Sandro J de Souza. Email sandro@. Abstract Technological advances have enabled a better characterization of all the genetic alterations in tumors. A picture that emerges is that tumor cells are much more genetically heterogeneous than originally expected. Thus a critical issue in cancer genomics is the identification of the genetic alterations that drive the genesis of a tumor. Recently a systems biology approach has been used to characterize such alterations and find associations between them and the process of gliomagenesis. Here we discuss some implications of this strategy for the development of new therapeutic and diagnostic protocols for cancer. Introduction One of the most important steps in the genesis of a tumor is the acquisition of both genetic and epigenetic alterations. Although a significant number of cancer-related genes have been identified in the past few decades 1 the emergence of technologies that allow genome-wide screening for alterations in large collections of tumors has affected the field of cancer biology in a dramatic way. The picture that is emerging is that most tumors are genetically heterogeneous and accumulate a large number of genetic and epigenetic alterations. The current level of genetic heterogeneity observed in tumors is nevertheless expected to increase in the next few years with the emergence of nextgeneration sequencing technologies. Collectively these technologies allow the detection of rare genetic variants present in less than 10 of the tumor cells and that cannot be .